Breaking News Instant updates and real-time market news.

EDIT

Editas Medicine

$29.00

1.36 (4.92%)

09:59
08/09/18
08/09
09:59
08/09/18
09:59

Editas Medicine management to meet with SunTrust

Meeting to be held in Boston on August 9 hosted by SunTrust.

  • 09

    Aug

EDIT Editas Medicine
$29.00

1.36 (4.92%)

03/07/18
LEHM
03/07/18
NO CHANGE
Target $46
LEHM
Overweight
Editas Medicine price target raised to $46 from $28 at Barclays
Barclays analyst Gena Wang raised her price target for Editas Medicine (EDIT) to $46 citing the company's technology platform and pipeline value. Several recent events, including the acquisitions of Kite and Juno and Sangamo (SGMO) collaboration with Gilead (GILD), validated the value of cell therapy and the potential of gene-editing technologies to serve as a powerful tool in developing next-generation products, Wang tells investors in a research note. She sees "strong upside potential" in Editas shares and keeps an Overweight rating on the name.
03/07/18
JMPS
03/07/18
NO CHANGE
Target $67
JMPS
Outperform
Editas Medicine price target raised to $67 from $40 at JMP Securities
JMP Securities analyst Michael King noted that Editas Medicine (EDIT) management highlighted with the Q4 earnings report that the company remains on track for a mid-2018 IND filing for EDIT-101 in LCA10. Management also highlighted that collaborator Juno Therapeutics (JUNO) plans to begin IND-enabling studies this year and to begin human clinical trials next year to treat human papillomavirus-associated solid tumors with T cells engineered using Editas' technology. Following the company's report of pipeline progress, and his own comparable company analysis, King raised his price target on Editas to $67 from $40 and keeps an Outperform rating on the shares.
06/11/18
MSCO
06/11/18
NO CHANGE
MSCO
Equal Weight
Editas CRISPR-related cancer risks seem overblown, says Morgan Stanley
After studies published in Nature Medicine by Novartis (NVS) and the Karolinska Institute suggested an increased risk of cancer that could result from editing genomes with CRISPR-Cas9, Morgan Stanley analyst Matthew Harrison said the concerns are theoretical and noted that STAT's article on the subject does not provide any link to an increased risk for CRISPR activation of p53 versus natural activation when DNA breaks. Harrison thinks theoretical concerns will continue to arise regarding gene editing until the first substantial set of clinical data is generated, but he does not see any direct concerns for Editas Medicine (EDIT) and expects the stock to recover in the coming days. He keeps an Equal Weight rating and $39 price target on Editas shares. Morgan Stanley does not cover Intellia Therapeutics (NTLA) or Crispr Therapeutics (CRSP), which have also seen weakness following the Nature Medicine publications.
07/18/18
JEFF
07/18/18
NO CHANGE
Target $40
JEFF
Buy
Study in Nature Biotech has limited readthrough to Intellia, says Jefferies
A new Nature Biotech publication highlights important safety points, but due to the methods/model systems used, the paper has limited readthrough to Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and Crispr Therapeutics (CRSP) programs advancing to the clinic, Jefferies analyst Maury Raycroft tells investors in a research note. The analyst believes the experiments used in the paper were not representative and may not have direct implications to current gene-editing clinical-directed strategies. The paper is another example of using a non-optimal model system with too many variables, Raycroft contends. He keeps a Buy rating on Intellia with a $40 price target.

TODAY'S FREE FLY STORIES

FBK

FB Financial

$33.54

-1.36 (-3.90%)

16:49
10/22/18
10/22
16:49
10/22/18
16:49
Hot Stocks
FB Financial authorizes $50M common stock repurchase program »

FB Financial's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 05

    Dec

  • 06

    Dec

FBK

FB Financial

$33.54

-1.36 (-3.90%)

16:48
10/22/18
10/22
16:48
10/22/18
16:48
Hot Stocks
FB Financial increases quarterly dividend 33% »

FB Financial Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 05

    Dec

  • 06

    Dec

SSB

South State

$73.05

-1.975 (-2.63%)

16:48
10/22/18
10/22
16:48
10/22/18
16:48
Earnings
South State reports Q3 adjusted EPS $1.33, consensus $1.40 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UVE

Universal Insurance

$47.72

0.72 (1.53%)

16:47
10/22/18
10/22
16:47
10/22/18
16:47
Hot Stocks
Universal Insurance announces expected financial impact from weather events »

Universal Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

HLT

Hilton

$70.17

-0.49 (-0.69%)

16:47
10/22/18
10/22
16:47
10/22/18
16:47
Initiation
Hilton initiated  »

Hilton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

SENS

Senseonics

$3.47

-0.14 (-3.88%)

16:46
10/22/18
10/22
16:46
10/22/18
16:46
Hot Stocks
Senseonics announces Aetna's positive coverage decision for Eversense »

Senseonics Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

16:44
10/22/18
10/22
16:44
10/22/18
16:44
Hot Stocks
Chembio Diagnostics acquires opTricon GmbH for $5.5M in cash »

Chembioannounced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

HLT

Hilton

$70.17

-0.49 (-0.69%)

16:43
10/22/18
10/22
16:43
10/22/18
16:43
Initiation
Hilton initiated  »

Hilton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

H

Hyatt

$69.50

-0.18 (-0.26%)

16:43
10/22/18
10/22
16:43
10/22/18
16:43
Initiation
Hyatt initiated  »

Hyatt initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

MAR

Marriott

$111.49

-0.58 (-0.52%)

16:42
10/22/18
10/22
16:42
10/22/18
16:42
Initiation
Marriott initiated  »

Marriott initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

16:41
10/22/18
10/22
16:41
10/22/18
16:41
Earnings
Chembio Diagnostics sees Q3 revenue $9.2M-$9.5M, two estimate consensus $8.05M »

Chembio Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CIEN

Ciena

$30.97

0.23 (0.75%)

16:41
10/22/18
10/22
16:41
10/22/18
16:41
Initiation
Ciena initiated  »

Ciena resumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSTM

HealthStream

$28.30

0.39 (1.40%)

16:40
10/22/18
10/22
16:40
10/22/18
16:40
Earnings
HealthStream sees FY18 revenue growth of 6%-8%, consensus $229.26M »

"Consistent with our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HSTM

HealthStream

$28.30

0.39 (1.40%)

16:38
10/22/18
10/22
16:38
10/22/18
16:38
Hot Stocks
HealthStream CFO Gerard Hayden, Jr. resigns, Scott Roberts named interim CFO »

HealthStream's CFO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

AFMD

Affimed N.V.

$3.15

-0.06 (-1.87%)

16:38
10/22/18
10/22
16:38
10/22/18
16:38
Syndicate
Breaking Syndicate news story on Affimed N.V. »

Affimed N.V. files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMD

ResMed

$102.58

-0.48 (-0.47%)

16:37
10/22/18
10/22
16:37
10/22/18
16:37
Hot Stocks
ResMed says it won German patent infringement case against Fisher & Paykel »

ResMed announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

FN

Fabrinet

$44.71

-0.3 (-0.67%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Initiation
Fabrinet initiated  »

Fabrinet resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$186.64

0.47 (0.25%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Hot Stocks
Wex signs agreement to acquire Noventis »

WEX announced the signing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 26

    Nov

GOOG

Alphabet

$1,100.52

4.11 (0.37%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Hot Stocks
Google's YouTube investing $20M in education resources for 'EduTubers' »

YouTube is investing $20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

HSTM

HealthStream

$28.30

0.39 (1.40%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Earnings
HealthStream reports Q3 EPS 9c, consensus 8c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WASH

Washington Trust

$52.03

-1.25 (-2.35%)

16:36
10/22/18
10/22
16:36
10/22/18
16:36
Earnings
Washington Trust reports Q3 EPS $1.01, consensus 98c »

"Washington…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FNSR

Finisar

$17.61

-0.19 (-1.07%)

16:34
10/22/18
10/22
16:34
10/22/18
16:34
Initiation
Finisar initiated  »

Finisar resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$45.76

-1.44 (-3.05%)

16:33
10/22/18
10/22
16:33
10/22/18
16:33
Earnings
Enterprise Financial reports Q3 core EPS 86c, consensus 89c »

Reports Q3 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$62.38

-0.7 (-1.11%)

16:33
10/22/18
10/22
16:33
10/22/18
16:33
Hot Stocks
Hexcel backs FY18 free cash flow greater than $230M »

Backs FY18 accrual basis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HXL

Hexcel

$62.38

-0.7 (-1.11%)

16:32
10/22/18
10/22
16:32
10/22/18
16:32
Earnings
Hexcel narrows FY18 adjusted EPS view to $2.99-$3.07 from 2.96-$3.10 »

FY18 consensus $3.03.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.